The Drug Delivery & Targeting (DDT) group develops new therapeutic strategies based on nanotechnology, in the field of oncology and rare diseases. During 2022 we have continued working in our research lines with important breakthroughs in all three of them -Design, synthesis and characterization of novel drug delivery systems (DDS) , either natural or synthetic. Incorporation of novel DDS to our portfolio (polymeric micelles, hydrogels and now solid lipid nanoparticles), standardization of the obtention and characterizatin of EVs with the incorporation of new isolation equipment. 4 funded projects. 1 ongoing clinical study. 6 publications –In vivo evaluation of synthetic and natural nanoparticles by means of devoted animal models and non-invasive imaging techniques.1 funded project. 2 publications. -Study of the molecular and cellular bases of the intercommunication between tumor cells and their environment. A PI22 granted to Dr. J. Seras-Franzoso. 1 publication.

Group Leader
Ibane Abasolo Olaortua

Principal Investigator (PI)
Joaquin Seras-Franzoso, Simó Schwartz Navarro

Researchers
Diana Fernandes Rafael, Fernanda da Silva Andrade, Vanessa Díaz-Riascos, Paula Zamora Pérez

PhD Students
Marc Moltó-Abad, Diego Baranda Martínez-Abascal, Francesc Martínez-Trucharte

Lab Technicians
Belén García-Prats, Begoña Fernández, Laura Mondejar Travería, Ignacio López Álvarez, Àngels Alcina Milà, Alejandra Palacio Arpi, Júlia Germàn Cortés

Nursing and Technical Staff
Laura García Latorre

10

PUBLICATIONS

80.0%

%Q1

71

IMPACT FACTOR

7.09

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Fernandez Y, Movellan J, Foradada L, Gimenez V, Garcia-Aranda N, Mancilla S, Arminan A, Borgos SE, Hyldbakk A, Bogdanska A, Gobbo OL, Prina-Mello A, Ponti J, Calzolai L, Zagorodko O, Gallon E, Nino-Pariente A, Paul A, Schwartz S Jr, Abasolo I, Vicent MJ
In Vivo anti-tumor and Metastatic Efficacy of A polyacetal-Based Paclitaxel Conjugate for Prostate Cancer Therapy
Fernandez Y, Movellan J, Foradada L, Gimenez V, Garcia-Aranda N, Mancilla S, Arminan A, Borgos SE, Hyldbakk A, Bogdanska A, Gobbo OL, Prina-Mello A, Ponti J, Calzolai L, Zagorodko O, Gallon E, Nino-Pariente A, Paul A, Schwartz S Jr, Abasolo I, Vicent MJ
DOI: doi: 10.1002/adhm.202101544
IF: 11.092

Andrade F, Roca-Melendres MM, Llaguno M, Hide D, Raurell I, Martell M, Vijayakumar S, Oliva M, Schwartz S Jr, Duran-Lara EF, Rafael D, Abasolo I
Smart and eco-friendly N-isopropylacrylamide and cellulose hydrogels as a safe dual-drug local cancer therapy approach
Carbohydr Polym. 2022 Nov 1;295:119859.
DOI: doi: 10.1016/j.carbpol.2022.119859
IF: 10.0723

Carton-Garcia F, Brotons B, Anguita E, Dopeso H, Tarragona J, Nieto R, Garcia-Vidal E, Macaya I, Zagyva Z, Dalmau M, Sanchez-Martin M, van Ijzendoorn SCD, Landolfi S, Hernandez-Losa J, Schwartz S Jr, Matias-Guiu X, Ramon Y Cajal S, Martinez-Barriocanal, Arango D
Myosin Vb as a tumor suppressor gene in intestinal cancer
Oncogene. 2022 Dec;41(49):5279-5288.
DOI: doi: 10.3390/ijms231911760
IF: 8.756

Luengo Y, Diaz-Riascos ZV, Garcia-Soriano D, Teran FJ, Artes-Ibanez EJ, Ibarrola O, Somoza A, Miranda R, Schwartz S Jr, Abasolo I, Salas G
Fine Control of In Vivo Magnetic Hyperthermia Using Iron Oxide Nanoparticles with Different Coatings and Degree of Aggregation
Pharmaceutics. 2022 Jul 22;14(8)
DOI: doi: 10.3390/pharmaceutics14081526
IF: 6.525

Camara-Sanchez P, Diaz-Riascos ZV, Garcia-Aranda N, Gener P, Seras-Franzoso J, Giani-Alonso M, Royo M, Vazquez E, Schwartz S Jr, Abasolo I
Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide
Int J Mol Sci. 2022 Oct 4;23(19)
DOI: doi: 10.3390/ijms231911760
IF: 6.208

Vesículas extracelulares para la mejora del tratamiento de las enfermedades de depósito lisosomal_PI21/00936
Principal Investigator: Ibane Abasolo Olaortua
Agency: Instituto de Salud Carlos iii
Funding: 153,670 €
Period: 2022-2024

MIMIC-KEY: A key to the rational design of extracellular vesicles-mimicking nanoparticles_GA 964386
Principal Investigator: Ibane Abasolo Olaortua
Agency: H2020- FETOPEN-2018-2019-2020-01
Funding: 457,250 €
Period: 2022-2024

Design of Nanoparticles for Blood-Brain-Barrier Crossing and Glioblastoma Multiforme Cancer Stem Cells Targeting (NanoGlio)_INVES211530DASI
Principal Investigator: Ibane Abasolo Olaortua
Agency: Asociación Española Contra el Cáncer
Funding: 100,000 €
Period: 2021-2023

Safety testing in the life cycle of nanotechnology enabled medical technologies for health_GA 814607
Principal Investigator: Ibane Abasolo Olaortua
Agency: H2020. DT-NMBP-02-2018
Funding: 633,518 €
Period: 2019-2023

Uso de nanobodies para terapia dirigida contra células madre tumorales_RTC2019-006809-1
Principal Investigator: Ibane Abasolo Olaortua
Agency: Ministerio de Ciencia e Innovación
Funding: 322,173 €
Period: 2020-2023

LIPOSOMES AND ITS USE FOR ENZYME DELIVERY
Priority Number: PCT/EP2022/051727
Priority Date: 26/01/2022
Applicants: 16 % VHIR, 28% CSIC, 24 % CIBER, 16 % Nanomol Technologies S.L, 16 % LEANBIO

CELL-PENETRATING PEPTIDES
Priority Number: PCT/EP2021/081100
Priority Date: 09/11/2021
Applicants: 90 % VHIR, 10 % CIBER

eCOREs